Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KLRB1 (CD161) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KLRB1 (CD161) ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View KLRB1 Products |
| Gene Delivery | KLRB1 (CD161) Promise-ORF / Lentivirus Full-length ORF for stable cell line generation to preserve native conformation. |
View KLRB1 Products |
| Benchmark Ab | Anti-KLRB1 (CD161) Recombinant Antibody Sequence-verified benchmark positive control based on clinical candidate BMS-986012. |
View KLRB1 Products |
| Validator | KLRB1 (CD161) siRNA Set For target knockdown verification in primary NK/T cells. |
View KLRB1 Products |
| Related Target A | CLEC2D The primary functional ligand for KLRB1 (CD161). Crucial for establishing receptor-ligand blocking assays. |
View CLEC2D Products |
| Related Target B | KLRG1 Co-inhibitory receptor on NK and T cells. Essential for off-target selectivity screening and combination studies. |
View KLRG1 Products |
| Related Target C | KLRC1 (NKG2A) Synergistic NK-cell immune checkpoint. Used for assessing multi-checkpoint blockade strategies. |
View KLRC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, mouse, and cynomolgus KLRB1 ortholog proteins available with >95% purity. |
| Subfamily counter screening | Homolog panel proteins (KLRG1, CD94) strictly verified by mass spectrometry and SDS-PAGE. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives | Validated siRNA included for specificity and functional knockdown checks. |
Live KLRB1 (CD161) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KLRB1 (CD161) therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific/multispecific antibodies and combination regimens. As first-generation therapies reach the clinic, the next wave of R&D is targeting the reversal of T and NK cell exhaustion in immunologically "cold" tumors, such as glioblastoma and immunotherapy-resistant non-small cell lung cancer (NSCLC).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Bristol Myers Squibb, Coherus BioSciences | Solid Tumors, Glioblastoma, NSCLC | CD161-CLEC2D blocking assay (Need high-purity ECD-Fc proteins) |
| Bispecific / NK Engager | Academic Institutions, Biotech Startups | Advanced Solid Tumors, Hematological | Dual-targeting validation (Need cross-reactive antigens and stable cell lines) |
| Cell Therapy (CAR-NK/T) | Biotech Innovators | Glioblastoma, Refractory Solid Tumors | Target knockout validation (Need sequence-verified siRNA and Lentivirus) |